NASDAQ NMS - GLOBAL MARKET · ANNX
-2.32% · -$0.1300 · Vol 2.0M
Market closed · last close 4:00 PM ET · price as of 17:07:52 ET
Annexon Inc

Annexon Inc

Biotechnology
$5.47
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
ANNX
Annexon Inc
Fri Aug 7 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

70/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 7 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ANNX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ANNX catalysts
About Annexon Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
93
Country
US

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$5.63
Day high
$5.70
Day low
$5.39
Previous close
$5.60
52W high
$6.96
-21.41% from high
52W low
$2.05
70% of range
Market cap
$886.4M
EPS
$-1.3100
Beta
1.04
Shares out
163.8M
Volume
2M
0.48× rel vol
Avg volume
4.2M
VWAP
$5.45
Price history computed in-house
1W
+7.36%
1M
-5.69%
3M
-3.70%
1Y
+131.78%
YTD
+8.96%
SMA 50 $5.36 · above
SMA 200 $5.18 · above
52W position 70%

ANNX overview

Veridion Score
70
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ANNX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ANNX Form 4 filings
Public disclosures

Congress activity in ANNX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ANNX in the cached public ledger.

Federal contracts

ANNX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ANNX in this window.
Lobbying spend

ANNX lobbying filings, year to date.

Registered lobbying filings matched to Annexon Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ANNX in this window.
Loading news for ANNX
Analyst ratings
Sovereign unlock shows live analyst consensus for ANNX.
Options
Sovereign unlock shows live options positioning for ANNX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.